Axon Therapies Raises $32 Mn in Series A Funding

The round was co-led by new investors Earlybird Venture Capital and Santé Ventures, with participation from existing investor Deerfield Management and new investors CD Capital and KOFA Healthcare.

Axon Therapies, a medtech company focused on heart failure therapies, has raised $32 million in an oversubscribed Series A funding round.

The round was co-led by new investors Earlybird Venture Capital and Santé Ventures, with participation from existing investor Deerfield Management and new investors CD Capital and KOFA Healthcare.

The company is developing Splanchnic Ablation for Volume Management (SAVM), a therapy that redirects blood volume from the heart to the abdominal region to reduce fluid overload and pulmonary capillary wedge pressure.

The funding will support clinical trials of the therapy for patients with Heart Failure with Preserved Ejection Fraction (HFpEF) and a multi-center study in Heart Failure with Reduced Ejection Fraction (HFrEF).

Alongside the funding, Axon announced that its cofounder and former chief scientific officer, Zoar Engelman, has been appointed CEO.

"Our implant-free, minimally invasive therapy is designed to address a core physiological driver of the disease. This funding positions us to advance to pivotal trials and bring hope to patients who urgently need new solutions," Engelman said.

In other deals, Caregility, an enterprise telehealth company, secured $25.1 million across Series A-2 Preferred Stock and Series C funding rounds, bringing its total raise to $92 million. Star Mountain Capital led the round, with participation from management, York Wang, initial founders and healthcare-focused investors.

The company said the funds will support its AI-driven initiatives, including computer vision, sensor-based tools, and ambient listening technology.

"Caregility is setting the standard for innovation in hospital-based virtual care, with groundbreaking capabilities such as edge-based Computer Vision AI and audio sensing room duress detection," said Dr. David Shulkin, independent board member of Caregility.

"Caregility has expanded these advancements globally, and their platform is uniquely positioned to redefine how hospitals deliver safe, efficient and high-quality care."

Daymark Health, a hybrid cancer care company, has raised $20 million in Series A funding. The round was led by Healthier Capital with participation from Blue Venture Fund and existing investors Maverick Ventures, Yosemite and Oncology Ventures.

The company partners with oncologists and primary care providers to offer virtual and in-home care for cancer patients, addressing clinical, social, and mental health needs. The new funds will be used to scale its platform and expand partnerships with health plans and providers nationwide.

AmplifyMD, a virtual care company serving hospitals and health systems, announced $20 million in Series B funding. Forerunner Ventures led the round, joined by Memorial Hermann Health System, F-Prime, Greylock and Tau Ventures.

Founded in 2019, AmplifyMD said it will use the capital to scale its platform with new AI and workflow tools while building more strategic partnerships.

"At Memorial Hermann, we look for innovation that addresses challenges in a fundamentally different way," said Feby Abraham, executive vice president and chief strategy officer at Memorial Hermann.

"AmplifyMD stands out because it combines AI-enabled workflows with on-demand specialty coverage, creating a scalable model that expands access, improves quality and lowers costs."

Stay tuned for more such updates on Digital Health News